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Abstract: G protein-coupled receptors (GPCRs) regulate intracellular signalling pathways that 
contribute to virtually all aspects of cell function. Characterising GPCRs in each of their 
conformational states is key to understanding their mechanism of action, but structure determination 
of receptors in their active state, bound to a heterotrimeric G protein or β-arrestin, has proved 
challenging. A number of G protein surrogates have been developed to simplify this process, 
including G protein-derived peptides, nanobodies and, most recently, mini G proteins. The aim of 
these surrogates is to bind the receptor and stabilise its active conformation, whilst eliminating the 
problems inherent to native signalling proteins, namely their large size, instability and 
conformational dynamics. Mini G proteins are composed of a single domain from the G protein  
α-subunit that has been engineered to form a stable complex with GPCRs. They induce comparable 
pharmacological and structural changes in the receptor to those elicited by heterotrimeric G proteins, 
and retain their native receptor-coupling specificity. At least one member of each G protein family 
has been converted into a mini G protein, which means that they can be used to characterise a wide 
variety of GPCRs. Since their initial publication two years ago, mini G proteins have facilitated the 
structure determination of three different receptors in their active state and enabled the development 
of a methodology to thermostabilise GPCRs in their fully active conformation. They have also been 
used to develop a range of assays that can measure mini G protein coupling to receptors in vitro, and 
a sensitive cell-based assay that is capable of accurately reporting ligand efficacy and quantifying G 
protein coupling in vivo. This review presents an overview of the current applications of mini G 
proteins to study the structure and function of GPCRs. 
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angiotensin II receptor; β1AR: β1-adrenergic receptor; β2AR: β2-adrenergic receptor; BRET: 
bioluminescence resonance energy transfer; CB1R: cannabinoid receptor type 1; CRF1R: 
corticotrophin-releasing factor receptor 1; cryo-EM: cryo-electron microscopy; CGRP: calcitonin 
gene-related peptide; CTR: calcitonin receptor; D1R: D1 dopamine receptor; D2R: D2 dopamine 
receptor; D5R: D5 dopamine receptor; ETAR: endothelin A receptor; GLP-1R: glucagon-like 
peptide 1 receptor; GPCR: G protein-coupled receptor; kDa: kilodalton; M3R: M3 acetylcholine 
receptor; M4R: M4 acetylcholine receptor; µOR: µ-opioid receptor; NTSR1: neurotensin receptor; 
PtdIns(4,5)P2: phosphatidylinositol-4,5-bisphosphate; V2R: vasopressin receptor 2 
1. Introduction 
G protein-coupled receptors (GPCRs) mediate cellular communication by regulating signal 
transduction through heterotrimeric G proteins and β-arrestins. This family of receptors represent one 
of the most important therapeutic targets for the pharmaceutical industry [1], and, as such, its members 
are key targets for structure determination. Crystallisation of GPCRs has proved to be one of the 
biggest challenges in structural biology in recent years, but one that has ultimately been overcome by 
technical innovation. The development and application of novel methodologies, including T4 lysozyme 
fusion proteins [2], conformational thermostabilisation [3] and lipidic cubic phase crystallisation [4,5], 
has resulted in 277 structures of 54 different receptors being determined to date [6]. These have 
provided unparalleled insight into the mechanism of ligand binding and receptor activation, and are 
currently being used by the pharmaceutical industry to facilitate the development of novel therapeutic 
compounds [7]. However, it has become evident that to understand the activation mechanism of 
individual receptors, and to fully exploit the potential of structure-based drug design, each receptor 
should ideally be characterised in a minimum of four distinct conformational states, bound to either: an 
inverse agonist; an agonist; an agonist and G protein; or an agonist and arrestin [8]. 
Structural and functional characterisation of GPCRs in their active conformation [8], i.e. bound 
to a heterotrimeric G protein [9] or β-arrestin [10], has proved to be particularly challenging, due to 
the large size, instability and conformational dynamics of these complexes [11,12]. Whilst it is true 
that structure determination of receptors bound to native signalling proteins is most desirable, the 
success rate of crystallising these complexes has been particularly low. Therefore, driven by the need 
to expedite the structure determination of receptors in their active conformation, a number of G 
protein mimetics have been developed, including G protein-derived peptides [13,14],  
nanobodies [15] and mini G proteins [16]. The aim of these surrogates is to bind the receptor and 
stabilise its active conformation, whilst eliminating the problems inherent to native signalling 
proteins. However, these mimetics have both advantages and disadvantages compared to 
heterotrimeric G proteins. The C-terminal peptide (GαCT) from the G protein α-subunit (Gα) is the 
smallest and simplest of the G protein mimetics, and it has facilitated the determination of numerous 
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active-state rhodopsin structures [13,17–22]. However, such peptides do not appear to efficiently 
stabilise the active conformation of other receptors, and are therefore of limited use for studying the 
wider GPCR family. Nanobodies have proved to be effective G protein surrogates that are able to 
induce comparable pharmacological and structural changes in the receptor to those elicited by 
heterotrimeric G proteins [23–27]. Their small size and rigid structure makes them particularly well 
suited to X-ray crystallography applications [28], but their inability to recapitulate the native GPCR-G 
protein interface means that these structures do not provide insight in to the molecular determinants 
of G protein coupling specificity. They also require laborious immunisation and selection procedures 
that must be performed for each receptor being studied. Mini G proteins (see Section 2) induce 
comparable pharmacological and structural changes in the receptor to those elicited by heterotrimeric 
G proteins, retain their natural coupling specificity [16,29] and recapitulate the native GPCR-G 
protein interface [30]. Mini G protein versions of at least one member of the four G protein families 
have been developed, they can therefore be used off-the-shelf to study a wide variety of receptors. 
However, the Gq class proved difficult to develop, and required the construction of chimeric proteins 
that are less biologically relevant [29]. 
Clearly, none of these surrogates represent a silver bullet for characterising GPCRs in their 
active conformation, and the stability of individual receptors remains a key factor in the success of 
structural studies. Nonetheless, together they comprise a toolkit of binding proteins that have 
greatly simplified the characterisation of active-state GPCRs, and have provided valuable insight 
into the mechanism of receptor activation. Mini G proteins are the latest addition to this toolkit, 
and, in this review, I present an overview of their current applications to study the structure and 
function of GPCRs. 
2. Development of mini G proteins 
The observation that led to the development of mini G proteins came from structure of the  
β2-adrenergic receptor (β2AR) in complex with heterotrimeric Gs [9]. Despite the G protein having a 
molecular weight of over 90 kDa, the structure revealed that virtually all of the molecular contacts 
that it formed with the receptor were mediated by the ~30 kDa GTPase domain from Gαs  
(Gαs-GTPase). The original mini G protein (mini-Gs) was constructed by isolating the Gαs-GTPase 
domain (Figure 1), and engineering it to increase its thermostability and reduce conformational 
dynamics. This was achieved using rational design mutagenesis, based primarily on the structure of 
Arl2 [31], the small G protein that is most structural similarity to Gαs [32]. The optimal construct 
contained deletions in three key regions, namely the α-helical domain (Gα-AH), switch III and the 
N-terminus. The Gα-AH domain was the most conformationally dynamic region in the β2AR–Gs 
complex [9,11]; its deletion not only reduced conformational dynamics, but also enabled the  
Gα-GTPase domain to couple receptors in the absence of the G protein βγ subunits (Gβγ) [16]. 
Switch III was disordered in the receptor-bound conformation [9], and is completely absent from 
small G proteins. Its deletion was designed to replace this flexible region with the defined secondary 
structure elements found in Arl2 [16,30,31]; this resulted in an increase in both the thermostability 
and expression level of the mini G protein [16]. The N-terminal helix normally interacts with Gβγ, 
and is therefore not explicitly required in the mini G protein. Deletion of the complete N-terminus 
had a detrimental effect on both the thermostability and expression level of the mini G protein, 
consequently, only residues 1–25 were deleted. Nevertheless, this removed a substantial region of 
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conformationally dynamic protein, and also eliminated the lipidation sites that tether Gα to the cell 
membrane [33]. The optimal construct also contained seven point mutations [16], none of which 
were located within the receptor-binding site. The G49D, E50N, A249D and S252D mutations were 
designed to stabilise the nucleotide-binding pocket and phosphate-binding loop; they resulted in 
increased thermostability of the mini G protein, as well as increased expression levels. The L272D 
mutation was incorporated to conformationally constrain the flexible switch II region. The I372A 
and V375I mutations, which are located within the α5 helix, were designed to stabilise the  
receptor-bound conformation of the mini G protein, particularly in the presence of detergent, by 
improving packing of the α5 helix against the core of the protein. The I372A mutation was also 
shown to render the complex largely resistant to dissociation by cellular concentrations of guanine 
nucleotides [16]. Residue I372 appears to act as a relay, transmitting the conformational 
rearrangements induced by receptor binding from the α5 helix to the nucleotide-binding pocket; the 
I372A mutation appears to prevent the propagation of these conformational changes, and thus 
uncouples receptor binding from nucleotide exchange [16]. The final mini-Gs construct was shown to 
induce a shift in the agonist-binding affinity of both the β1-adrenergic receptor (β1AR) and the 
adenosine A2A receptor (A2AR) comparable to that elicited by Gs, demonstrating that it functioned as 
an effective mimetic of the heterotrimeric G protein [16,30]. To prove that mini-Gs could facilitate 
the structure determination of a receptor in its active state, it was crystallised in complex with A2AR, 
and the structure solved at 3.4 Å resolution [30,34] (see Section 3.2). Comparison of this structure 
with that of β2AR–Gs revealed striking similarities in the organisation of the complex. Critically, the 
α5 helix and C-terminus of the mini G protein undergo comparable conformational changes to those 
observed in the heterotrimeric G protein, demonstrating that the mini G protein does indeed 
recapitulate the native GPCR-G protein interface [30]. 
 
Figure 1. Development of the original mini G protein. A: Structure of β2AR in complex 
with heterotrimeric Gs and a nanobody (Nb35) that stabilised the complex [9]. Despite 
the G protein having a molecular weight of over 90 kDa, virtually all of the residues that 
interact with the receptor (shown as spheres) were localised to the Gαs-GTPase domain 
(coloured cyan). B: Model of a mini G protein in complex with a receptor. A truncated, 
engineered version of the Gα-GTPase domain, with a molecular weight of ~27 kDa, was 
developed to act as a functional mimetic of the heterotrimeric G protein [16]. Figures 
prepared using PyMOL (The PyMOL Molecular Graphics System, Version 1.8.4 
Schrödinger, LLC). 
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Following the successful development of mini-Gs, the concept was transferred to the other 
classes of heterotrimeric G proteins; the goal being to convert at least one member of each family 
into a mini G protein [29]. To date, this has been directly achieved for members of the Gs, Gi and 
G12 families (see Table 1 for details), but only indirectly for Gq family members (discussed below). 
Mini-Gq could not be expressed in a functional form, so instead a chimera was constructed, in which 
residues from mini-Gs that interact with either A2AR or β2AR in the respective crystal structures [9,30] 
were mutated to match those found in Gq. This approach is not ideal since it cannot account for 
structural differences between Gs and Gq, or variations in the molecular contacts that they form with 
Gs- or Gq-coupled receptors, respectively. Nonetheless, the mini-Gs/q chimera did interact with Gq-coupled 
receptors such as the neurotensin receptor (NTSR1) and the angiotensin II receptor (AT1R), and did 
not bind Gs-coupled receptors such as A2AR [29]. Therefore, it is a useful tool for the functional 
characterisation of Gq-coupled receptors, but, since it is unlikely to fully stabilise the receptor in its 
active state or perfectly recapitulate the native GPCR-G protein interface, it may not be the best option 
for structural studies. Development of mini-Gi also proved difficult, and so a chimera with mini-Gs 
(mini-Gs/i) was constructed. This has been used successfully in cell-based assays (see Section 4.2), 
although mini-Go remains the best Gi family member for structural studies (see Table 1). 
Table 1. Mini G proteins. 
Family Mini G proteins GPCRs shown to bind 
in vitroa 
GPCRs shown to bind 
in vivob 
Structures determined 
Gs mini-Gs A2AR A2AR A2AR–mini-Gs 
    A2AR–mini-Gs–β1γ2c 
  β1AR   
   β2AR  
   D1R  
   D5R  
   V2R  
 mini-Golf A2AR   
Gi mini-Gi1 5-HT1BR   
 mini-Gs/i1d 5-HT1BR   
   α2A-AR  
   A1R  
   CB1R  
   D2R  
   M4R  
 mini-Go1 5-HT1BR  5-HT1BR–mini-Go1–β1γ2c 
  Rhodopsin  Rhodopsin–mini-Go1 
Gq mini-Gs/qd NTSR1   
  AT1R AT1R  
   ETAR  
   M3R  
   5-HT2AR  
                                                                                                      Continued on next page 
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Family Mini G proteins GPCRs shown to bind 
in vitroa 
GPCRs shown to bind 
in vivob 
Structures determined 
G12 mini-G12 None Nonee  
a Detergent-solubilised or membrane embedded GPCRs. 
b Primary coupling interactions. 
c Heterotrimeric versions of the mini G proteins. 
d Chimeric mini G proteins. 
e Only secondary coupling interactions have been observed for mini-G12 in vivo [35]. 
Mini G proteins have a number of advantages in structural biology applications, compared to 
the heterotrimeric G proteins from which they were derived, including their smaller size (~27 kDa), 
reduced conformational dynamics, increased solubility and improved thermostability, particularly in 
short-chain detergents. They also exhibit additional characteristics that have broadened their range of 
applications, including: (i) their high-level expression (up to 100 mg/l) in E. coli [36], which makes 
them both simple and inexpensive to produce in large quantities, and thus ideal for high-throughput 
screening applications (see Section 3.1); (ii) their potential modification to restore binding to Gβγ, 
which is particularly useful in cryo-electron microscopy (cryo-EM) applications (see Section 3.2); 
and (iii) their resistance to dissociation from the receptor by physiological concentrations of  
GTP [16], which allows them to be used in cell-based assays (see Section 4.2). 
3. Structural biology applications of mini G proteins 
Mini G proteins have been used to both improve the properties of receptors for structural 
studies (see Section 3.1), and to facilitate structure determination of GPCRs in their active state 
(see Section 3.2). To date, structures of three different receptors have been solved in complex with 
mini G proteins, using either X-ray crystallography or cryo-EM, namely A2AR [30,37], the 
serotonin 5-HT1B receptor (5-HT1BR) [38] and rhodopsin [39]. Interestingly, structures of the A2AR 
complex have been solved using both approaches, which has enabled direct comparison of 
these techniques [37]. 
3.1. Thermostabilisation of GPCRs for structural studies 
GPCRs are extremely labile when extracted from the membrane by detergent solubilisation, and 
the relative stability of individual receptors is a key factor in whether or not their structure can be 
determined. At present, structures have been reported for only ~15% of non-olfactory GPCRs 
encoded in the human genome. Considering that these receptors have often been selected for 
characterisation based on their above-average stability, it is telling that the vast majority have only 
had their structures determined bound to an antagonist, which is typically the most stable 
conformation. One solution to this problem has been the development of conformational 
thermostabilisation, which uses systematic mutagenesis coupled with a radioligand binding assay to 
stabilise detergent-solubilised receptors in a defined conformational state [3]. This approach has 
previously been used to increase the thermostability of either antagonist- or agonist-bound receptors 
sufficiently to facilitate their crystallisation [3,40–42]. Notably, conformational thermostabilisation 
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of A2AR in the presence of an agonist alone did not result in stabilisation of the fully active state, but 
rather a biologically relevant intermediate-active conformation [40,41,43–46]. This suggests that in 
order to stabilise the fully active state of the receptor, both the agonist and G protein must be present 
during the selection process. 
Using heterotrimeric G proteins in this type of conformational thermostabilisation procedure 
poses several problems. First, G proteins are composed of multiple subunits, which may be 
susceptible to dissociation when heated in the presence of detergent. Second, to ensure saturation of 
the receptor, the G protein must be added at a relatively high concentration (ideally in the 
micromolar range), which would potentially require hundreds of milligrams of G protein to conduct 
a full screen. Third, the heterotrimer must be expressed in insect cells using the baculovirus 
expression system, which means that producing large quantities of pure protein is both time 
consuming and expensive. In contrast, mini G protein are small, single domain proteins that are 
highly expressed in E. coli, and stable even in harsh detergent [16]. The advent of mini G proteins 
has therefore enabled conformational thermostabilisation to be applied to an agonist–GPCR–G 
protein complex, namely the corticotrophin-releasing factor receptor 1 (CRF1R) in complex with the 
peptide agonist sauvagine and mini-Gs [47]. The initial screen identified 17 individual point 
mutations that increased the apparent melting temperature (Tm) of the sauvagine–CRF1R–mini-Gs 
complex by up to 5.1 °C. These results are comparable to those obtained during the initial 
thermostability screen of agonist-bound A2AR [40], which ultimately resulted in its successful 
crystallisation [41], suggesting that conformational thermostabilisation is indeed a viable approach 
for stabilising agonist–GPCR–G protein complexes. 
3.2. Structure determination of GPCRs in their active conformation 
Mini G proteins were originally developed to facilitate structure determination of receptors in 
their active conformation using X-ray crystallography. Only one structure of a GPCR bound to a 
heterotrimeric G protein has been solved using this approach, namely the β2AR–Gs complex, and 
even this required a nanobody (Nb35) to stabilise the complex sufficiently to enable its 
crystallisation [9] (Figure 1A). Mini G proteins have facilitated the determination of two additional 
structures by X-ray crystallography. The structure of A2AR bound to mini-Gs and the agonist NECA 
was solved at 3.4 Å resolution by vapour diffusion crystallisation in the detergent octylthioglucoside 
(OTG) [30] (Figure 2A). This was the first structure of A2AR to be solved in its active conformation, 
and it completed a series of structures comprising the inactive, intermediate-active and active states 
that provided unparalleled insight in the activation mechanism of this receptor [48]. The structure of 
rhodopsin bound to mini-Go and all-trans retinal was solved at 3.1 Å resolution by vapour diffusion 
crystallisation in the detergent octyl glucose neopentyl glycol (OGNG) [39] (Figure 2A). In the 
visual system, rhodopsin naturally couples to transducin (Gt), which is a member of the Gi family; 
attempts to construct a mini G protein version of Gt were unsuccessful, so crystallisation was 
performed using another Gi family member, mini-Go (see Table 1). This structure revealed that a 
common active conformation of rhodopsin is responsible for coupling both the G protein and  
arrestin [10,39]. It is noteworthy that both of these mini G protein complexes were crystallised by 
vapour diffusion, since high-quality crystals could not be obtained using LCP. The β2AR–Gs 
complex however was crystallised using LCP [9], so this method should also be compatible with 
mini G proteins. It is likely that further screening will be required to identify the optimal combination of 
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detergent, lipids and additives to successfully crystallise mini G protein complexes using this 
approach. 
 
Figure 2. Structures of GPCRs in complex with mini G proteins. A: Structures of two 
mini G protein complexes have been solved using X-ray crystallography: A2AR bound to 
mini-Gs and the agonist NECA (PDB: 5G53) [30]; and rhodopsin bound to mini-Go and 
all-trans retinal (PDB: 6FUF) [39]. B: Structures of two heterotrimeric mini G protein 
complexes have been solved using cryo-EM: A2AR bound to mini-Gs–β1γ2, NECA and 
Nb35 (PDB: 6GDG) [37], and 5HT1BR bound to mini-Go–β1γ2 and the agonist 
donitriptan (PDB: 6G79) [38]. 
Recent advances in cryo-EM have brought this technique to the forefront of efforts to determine 
structures of GPCR–G protein complexes. During the past two years it has accounted for structures 
of three receptors in complex with Gs, namely the calcitonin receptor (CTR) [49], the calcitonin  
gene-related peptide (CGRP) receptor [50] and the glucagon-like peptide 1 receptor (GLP-1R) [51], 
as well as three receptors in complex with Gi, namely the µ-opioid receptor (µOR) [52], the 
adenosine A1 receptor (A1R) [53] and rhodopsin [54]. Despite the fact that cryo-EM is currently 
limited to proteins larger than ~65 kDa [55], which is similar to that of a receptor in complex with a 
mini G protein, it has not yet proved possible to resolve such complexes using this approach. 
However, mini G proteins can easily be modified to restore binding to Gβγ [16], and these 
heterotrimeric versions have facilitated the determination of two structures using cryo-EM. The 
structure of A2AR bound to mini-Gs–β1γ2 and the agonist NECA was solved at 4.1 Å resolution in the 
detergent lauryl maltose neopentyl glycol (LMNG) [37] (Figure 2B). The organisation of the 
interface in this structure was virtually identical to that in the A2AR–mini-Gs complex solved using 
X-ray crystallography, which further validates the use of mini G proteins as surrogates for 
heterotrimeric G proteins. The structure of 5-HT1BR bound to mini-Go–β1γ2 and the agonist 
donitriptan was solved at 3.8 Å resolution in the detergent decylmaltoside (DM) [38] (Figure 2B). 
This was the first structure of a receptor to be solved in complex with Go, and it provided unique 
insight into the molecular determinants of G protein coupling specificity. 
At present, it is unclear whether the heterotrimeric versions of mini G proteins have a 
significant advantage over native heterotrimeric G proteins in cryo-EM applications. While mini G 
proteins do lack the conformationally dynamic Gα-AH domain [16], this is not necessarily an 
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advantage in cryo-EM, since flexible regions can easily be masked and omitted from data processing. 
Furthermore, cryo-EM is compatible with milder long-chain detergents, in which the stability of 
complexes composed of either a mini G protein or heterotrimeric G protein appear to be similar [16], 
although this has not been extensively tested. The use of mini G protein heterotrimers does enable 
shorter chain detergents such as DM to be screened during sample preparation for cryo-EM; an 
approach that significantly improved the homogeneity of the 5-HT1BR complex (R. Nehmé, personal 
communication). Furthermore, if technical developments continue to reduce the protein size limit for 
cryo-EM [56], then, in the future, it may be possible to determine structures of GPCRs in complex 
with the mini G protein alone. This would significantly increase the throughput of complex preparation 
and screening, which should translate into an increased rate of successful structure determination. 
4. Applications of mini G proteins for the functional characterisation of GPCRs 
Mini G proteins have been used in a number of applications to functionally characterise GPCRs. 
In vitro, they have been used to develop a suite of easy-to-use assays that are capable of reporting 
mini G protein binding to either membrane-embedded or detergent-solubilised receptors. They have 
also been used in a cutting-edge native mass spectrometry study to identify endogenous lipids that 
modulate GPCR-G protein interactions. In vivo, they have been used to develop a sensitive assay that 
is capable of accurately quantifying mini G protein coupling to variety of receptors. 
4.1. Characterising G protein coupling to GPCRs in vitro 
In many cases, simply detecting G protein binding to a receptor in vitro is extremely 
challenging, particularly when working with detergent-solubilised samples. This means that there is 
no single assay that is suitable for characterising G protein coupling to the entire GPCR family. 
Therefore, five different assays have been developed to monitor mini G protein coupling to a range 
of different GPCRs. First, a competition binding assay was used to demonstrate mini G protein 
coupling to membrane-embedded A2AR [30,37], β1AR [16] and 5-HT1BR [29]. This assay measures 
the inhibitory constant (Ki) of an agonist binding to a receptor in either the presence or absence of a 
mini G protein (Figure 3A). For many receptors, G protein binding elicits a significant increase (10 
to 100-fold) in their agonist-binding affinity [57], and, in these cases, the competition binding assay 
can be used to reliably measure mini G protein coupling. The advantages of this assay are that it is 
very sensitive and can be performed in high-throughput format. The disadvantages are that a 
radiolabelled antagonist is required for each receptor being investigated and some receptors exhibit 
only a small shift in agonist-binding affinity upon G protein coupling, in which case this assay is not 
suitable. Second, a thermostability assay [3] was used to report binding of mini G proteins to 
detergent-solubilised A2AR [29,30], AT1R [29], β1AR [16], CRF1R [47], NTSR1 [29] and  
5-HT1BR [29]. This assay measures the apparent Tm of a non-purified detergent-solubilised receptor 
in the presence of either an agonist, or both an agonist and a mini G protein (Figure 3B). All 
receptors that have been tested in this assay display higher thermostability when bound to both the 
agonist and mini G protein, compared to the agonist alone; this response can therefore be used as a 
reliable indicator of mini G protein coupling. The advantages of this assay are that it can be used to 
evaluate the stability of the complex in different detergents and can be performed in high-throughput. 
The main disadvantage is that, in this format, a radiolabelled agonist is required for each receptor 
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being investigated. However, it may be possible to use a different type of thermostability assay that 
does not require a radioligand, such as differential scanning fluorimetry (DSF) [58], although this has 
not been tested. Third, fluorescence size exclusion chromatography (FSEC) was used to evaluate 
mini G protein coupling to non-purified detergent-solubilised A2AR, β1AR and 5-HT1BR [29]. In this 
approach, samples of a GFP-tagged mini G protein, either alone or mixed with a non-purified 
detergent-solubilised receptor bound to either an agonist or antagonist, are loaded onto a gel filtration 
column and GFP signal in the eluate is monitored using a fluorescence detector. A shift in the 
retention volume of the GFP-tagged mini G protein peak in the presence of the agonist-bound 
receptor is indicative of complex formation (Figure 3C). The advantages of this assay are that it uses 
non-purified receptor samples and it allows rapid screening of detergent or buffer conditions for 
optimal complex formation. The disadvantages are that only a low concentration of GFP-tagged mini 
G protein can be used in the assay and high detergent concentrations are often required for efficient 
membrane solubilisation, which can affect the stability of the complex. Fourth, a fluorescence 
saturation binding assay (FSBA) was used to estimate the affinity of mini G protein binding to 
detergent-solubilised A2AR, β1AR and 5-HT1BR [29]. This assay measures the apparent 
equilibrium dissociation constant (KD) of a GFP-tagged mini G protein binding to a non-purified 
detergent-solubilised receptor, immobilised on a microtiter plate via its histidine tag, in the presence 
of either an agonist or antagonist (Figure 3D). The main advantage of this assay is that it can be used 
to estimate G protein binding affinity in different detergents or buffers. The main disadvantage is that 
the affinity of the interaction is likely to be affected by the presence of detergent, and thus is not 
representative of native interactions within the cell. Fifth, analytical gel filtration chromatography 
was used to demonstrate mini G protein binding to A2AR [29], β1AR [16] and 5-HT1BR [29]. In this 
approach, samples of purified receptor and mini G protein, either individually or mixed, are resolved 
by analytical gel filtration chromatography. A decrease in the retention volume of the mixed sample, 
compared to the receptor alone, indicates complex formation (Figure 3E). Also, co-elution of the 
receptor and mini G protein, which is assessed by SDS-PAGE analysis of the gel filtration eluate, 
gives a reliable indication of coupling (Figure 3F). The advantages of this method are that it can be 
used to screen detergents or buffer conditions for optimal complex formation and it enables the 
stability of a complex to be assessed over a period of days. The main disadvantage is that it requires 
a significant quantity of purified receptor, which can be challenging to obtain. 
Mini G proteins have also been used to study the effect of endogenous lipids on the G protein 
coupling selectivity of A2AR, β1AR and NTSR1 using native mass spectrometry [59]. Hotspots were 
identified on the cytoplasmic surface of the receptors that specifically bound  
phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2). This lipid appears to function as an allosteric 
modulator of G protein binding, by both stabilising the active state of the receptor and mediating 
bridging interactions with the G protein. Mini G proteins proved ideal for this application, since they 
are more stable than heterotrimeric G proteins, and, whilst nanobodies could also be used, they did 
not bind PtdIns(4,5)P2 and thus did not recapitulate the native bridging interactions. 
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Figure 3. Five different assays have been developed to characterise mini G protein 
coupling to a range of GPCRs in vitro; the example of mini-Gs binding to β1AR is used 
to illustrate each assay. A: A competition binding assay that measures the Ki of agonist 
binding to membrane-embedded receptors in either the presence or absence of a mini G 
protein. Coupling to mini-Gs resulted in an increase in the isoprenaline-binding affinity 
of β1AR by ~10-fold [16]. B: A thermostability assay that measures the apparent Tm of 
non-purified detergent-solubilised receptors in either the presence or absence of a mini G 
protein. Coupling to mini-Gs resulted in an increase in the thermostability of  
DDM-solubilised β1AR by ~8 °C [16]. C: Fluorescence size exclusion chromatography 
(FSEC) that measures binding of a GFP-tagged mini G protein to non-purified  
detergent-solubilised receptors. In the presence of DDM-solubilised β1AR and the 
inverse agonist ICI118551 no shift was observed in the retention volume of GFP-mini-Gs 
(15.1 ml), but in the presence of β1AR and the agonist isoprenaline the retention volume 
shifted to 12.1 ml, demonstrating complex formation; a peak of aggregated protein was 
also observed in the void volume of the column (8 ml) [29]. D: A fluorescence saturation 
binding assay (FSBA) that measures the apparent KD of a GFP-tagged mini G protein 
binding to non-purified detergent-solubilised receptors. Non-specific binding of  
GFP-mini-Gs to DDM-solubilised β1AR was measured in the presence of the inverse 
agonist ICI118551, this was subtracted from the total binding measured in the presence 
of the agonist isoprenaline to give specific binding; the apparent KD was 200 nM [29]. E: 
Analytical gel filtration chromatography that measures mini G protein coupling to 
purified detergent-solubilised receptors. Mini-Gs had a retention volume of 17.1 ml and 
DDM-solubilised β1AR had a retention volume of 13.2 ml, compared to a retention 
volume of 12.9 ml for the β1AR–mini-Gs complex [16]. F: SDS-PAGE analysis of the gel 
filtration eluate confirmed that the receptor and mini G protein co-eluted [16]. 
4.2. Characterising G protein coupling to GPCRs in vivo 
Mini G proteins have been used to measure G protein coupling to GPCRs in live mammalian 
cells using confocal microscopy, bioluminescence resonance energy transfer (BRET) spectroscopy 
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and luciferase complementation [35]. Initially, confocal microscopy was used to demonstrate 
agonist-dependent recruitment of mini-Gs (fused to the fluorescent protein venus) to  
membrane-localised β2AR. This confirmed that the resistance of mini G protein complexes to 
dissociation by cytosolic concentrations of guanine nucleotides makes them ideally suited to  
cell-based applications. Next, a BRET spectroscopy assay was developed using mini G proteins from 
each of the four families. Mini-Gs and mini-G12 were both well expressed in mammalian cells, but 
neither mini-Gq or mini-Gi were expressed in a soluble form, therefore the chimeric versions of these 
proteins, mini-Gs/i and mini-Gs/q, were used (see Table 1). BRET was measured between  
venus-tagged versions of these mini G proteins and a panel of GPCRs (fused to the Renilla luciferase 
Rluc8). The cytosolic localisation of mini G proteins means that they displayed a significantly higher 
BRET signal-to-noise ratio than heterotrimeric G proteins [60,61], which are tethered to the 
membrane through lipid anchors [33]. The assay was able to accurately profile coupling of the mini 
G proteins to a panel of receptors including: The α2A-adrenergic receptor (α2A-AR); A1R; A2AR; 
AT1R; β2AR; the cannabinoid receptor type 1 (CB1R); the D1, D2 and D5 dopamine receptors (D1R, 
D2R and D5R, respectively), the endothelin A receptor (ETAR); the M3 and M4 acetylcholine 
receptors (M3R and M4R, respectively); the serotonin 5-HT2A receptor (5-HT2AR); and the 
vasopressin receptor 2 (V2R; see Table 1). The mini G proteins, including the two chimeras, were 
shown to maintain appropriate coupling specificity in vivo (see Table 1). Furthermore, their 
secondary coupling interactions were also accurately reported, and in the case of D1R and D5R, 
previously unknown secondary interactions were also identified. The assay was also able to precisely 
report the efficacy of agonists, partial agonists, antagonists and inverse agonists at β2AR by 
measuring mini-Gs coupling [35]. Similar results were obtained when the assay was modified to use 
luciferase complementation [62], demonstrating the versatility of this assay format. Confocal 
microscopy and BRET spectroscopy were also used to measure mini G protein recruitment to 
receptors localised to intracellular compartments, including A1R in the Golgi apparatus and β2AR in 
early endosomes [35]. Thus, mini G proteins can be used as biosensors for monitoring the subcellular 
localisation and internalisation of receptors in a similar manner to nanobodies [63,64]. 
5. Conclusions and future perspectives 
Mini G proteins have facilitated the structure determination of three different receptors in their 
active state, and have enabled the development of a novel methodology to thermostabilise  
agonist–GPCR–G protein complexes. These structures have provided valuable insight into the mode 
of agonist binding, the mechanism of receptor activation, and the molecular determinants of G 
protein coupling specificity. Their potential applications in structure-based drug design means there 
is high demand for structures of all GPCRs to be solved in their active state; both cryo-EM and X-ray 
crystallography will be key techniques in determining these structures, and mini G proteins have 
proven to be useful tools in both approaches. Beyond structural biology, mini G proteins have been 
used to develop a range of assays that have facilitated the characterisation of G protein coupling both 
in vitro and in vivo. The cell-based BERT spectroscopy assay will have immediate applications in 
GPCR drug discovery, enabling the efficacy and functional selectivity [65] of novel drug candidates 
to be measure at potentially any receptor. It will also facilitate the characterisation of allosteric 
modulators that can be used to enhance the receptor subtype specificity of orthosteric ligands [66]. 
The construction of some mini G protein subtypes has proved difficult, particularly Gq family 
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members, thus further work is required to complete development of the full mini G protein panel. 
The relatively high degree of sequence homology shared by the different mini G proteins means that 
it should be possible to use gene shuffling approaches to pinpoint areas responsible for the poor 
stability of certain subtypes. This would enable the development of more biologically relevant 
chimeras in which only minimal regions of the mini G protein need to be substituted to achieve 
optimal expression and stability [67]. Although a number of different tools are available for 
characterising receptors in their active state, the fact that mini G proteins can be used off-the-shelf 
without the need for laborious receptor-specific development makes them an ideal first choice in 
many applications. Further development and modification of mini G proteins should result in many 
more novel applications being identified, particularly in relation to GPCR functional studies. 
Therefore, in the future, mini G proteins will continue to contribute to our understanding of these 
important receptors, and aid in the development of drugs to treat a wide variety of diseases. 
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